These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Neural stem cell therapy for neurovascular injury in Alzheimer's disease. Boese AC; Hamblin MH; Lee JP Exp Neurol; 2020 Feb; 324():113112. PubMed ID: 31730762 [TBL] [Abstract][Full Text] [Related]
24. The Contribution of Cerebral Vascular Neuropathology to Mild Stage of Alzheimer's Dementia Using the NACC Database. Liu Y; Chan DK; Crawford JD; Sachdev PS; Braidy N Curr Alzheimer Res; 2020; 17(13):1167-1176. PubMed ID: 33583381 [TBL] [Abstract][Full Text] [Related]
26. Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer's Disease. Grossmann K Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009437 [TBL] [Abstract][Full Text] [Related]
27. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Poirier J Ann N Y Acad Sci; 2000; 924():81-90. PubMed ID: 11193807 [TBL] [Abstract][Full Text] [Related]
28. The Neurovascular Unit Dysfunction in Alzheimer's Disease. Soto-Rojas LO; Pacheco-Herrero M; Martínez-Gómez PA; Campa-Córdoba BB; Apátiga-Pérez R; Villegas-Rojas MM; Harrington CR; de la Cruz F; Garcés-Ramírez L; Luna-Muñoz J Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670754 [TBL] [Abstract][Full Text] [Related]
29. Pathological changes within the cerebral vasculature in Alzheimer's disease: New perspectives. Fisher RA; Miners JS; Love S Brain Pathol; 2022 Nov; 32(6):e13061. PubMed ID: 35289012 [TBL] [Abstract][Full Text] [Related]
30. [Traumatic brain injury as risk factor of Alzheimer's disease and possibilities of pathogenetic therapy]. Litvinenko IV; Naumov KM; Lobzin VY; Emelin AY; Dynin PS; Kolmakova KA; Nikishin VO Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(1):45-54. PubMed ID: 38261283 [TBL] [Abstract][Full Text] [Related]
31. Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia. Uemura MT; Maki T; Ihara M; Lee VMY; Trojanowski JQ Front Aging Neurosci; 2020; 12():80. PubMed ID: 32317958 [TBL] [Abstract][Full Text] [Related]
32. New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Zlokovic BV Neurotherapeutics; 2008 Jul; 5(3):409-14. PubMed ID: 18625452 [TBL] [Abstract][Full Text] [Related]
33. Endothelial Mitochondrial Dysfunction in Cerebral Amyloid Angiopathy and Alzheimer's Disease. Parodi-Rullán R; Sone JY; Fossati S J Alzheimers Dis; 2019; 72(4):1019-1039. PubMed ID: 31306129 [TBL] [Abstract][Full Text] [Related]
34. Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Janelidze S; Hertze J; Nägga K; Nilsson K; Nilsson C; ; Wennström M; van Westen D; Blennow K; Zetterberg H; Hansson O Neurobiol Aging; 2017 Mar; 51():104-112. PubMed ID: 28061383 [TBL] [Abstract][Full Text] [Related]
35. Vascular dysfunction in the pathogenesis of Alzheimer's disease--A review of endothelium-mediated mechanisms and ensuing vicious circles. Di Marco LY; Venneri A; Farkas E; Evans PC; Marzo A; Frangi AF Neurobiol Dis; 2015 Oct; 82():593-606. PubMed ID: 26311408 [TBL] [Abstract][Full Text] [Related]
36. Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder? Kelleher RJ; Soiza RL Am J Cardiovasc Dis; 2013 Nov; 3(4):197-226. PubMed ID: 24224133 [TBL] [Abstract][Full Text] [Related]
37. Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's disease. Canobbio I; Abubaker AA; Visconte C; Torti M; Pula G Front Cell Neurosci; 2015; 9():65. PubMed ID: 25784858 [TBL] [Abstract][Full Text] [Related]
38. Emerging roles of astrocytes in blood-brain barrier disruption upon amyloid-beta insults in Alzheimer's disease. Yue Q; Hoi MPM Neural Regen Res; 2023 Sep; 18(9):1890-1902. PubMed ID: 36926705 [TBL] [Abstract][Full Text] [Related]